Phase I Study of the Antiangiogenic Antibody Bevacizumab and the mTOR/Hypoxia-Inducible Factor Inhibitor Temsirolimus Combined with Liposomal Doxorubicin: Tolerance and Biological Activity
Authors:
- 14 October 2012
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 18 (20) , 5796-5805
Abstract
Purpose: Preclinical data suggest that combining the mTOR/hypoxia-inducible factor (HIF) inhibitor temsirolimus and the antiangiogenesis antibody bevacizumab may augment antitumor activity as well as resensitize cells to anthracyclines. Experimental Design: We initiated a phase I study of bevacizumab and temsirolimus plus liposomal doxorubicin in patients with advanced malignancies. Patients (N = 136) were enrolled according to a modified 3 + 3 design plus dose expansion in responsive tumor types. Results: The most common cancers were breast (n = 29), epithelial ovarian (n = 23), and colorectal cancer (n = 17). The median number of prior chemotherapy regimens was four (range: 0–16). Grade 3 or higher adverse events (> 5%) included pancytopenia, mucositis, hand–foot syndrome, hypertension, and fistula. This regimen led to a 21% (n = 28) stable disease (SD) ≥ 6 months and 21% (n = 29) rate of partial or complete remission [PR/CR; (total SD ≥ 6 months/PR/CR = 42% (n = 57)]. PR/CR was most common in parotid gland adenocarcinoma (4/6, 67%), metaplastic breast cancer (5/12, 42%), endometrial endometrioid carcinoma (6/15, 40%), and in patients with a PIK3CA mutation and/or a PTEN mutation/loss (11/28, 39%). The maximum tolerated dose was liposomal doxorubicin 30 mg/m2 and bevacizumab 15 mg/kg every three weeks with temsirolimus 25 mg weekly. Conclusions: Patients tolerated bevacizumab and temsirolimus together with liposomal doxorubicin. Further evaluation, especially in patients with parotid, metaplastic breast, and endometrial endometrioid cancer, and in patients with PIK3CA and/or PTEN aberrations is warranted. Clin Cancer Res; 18(20); 5796–805. ©2012 AACR.Keywords
This publication has 34 references indexed in Scilit:
- The unfolded protein response protects human tumor cells during hypoxia through regulation of the autophagy genes MAP1LC3B and ATG5Journal of Clinical Investigation, 2010
- Molecular Mechanisms of Resistance to Tumour Anti-Angiogenic StrategiesJournal of Oncology, 2010
- Silencing or Fueling Metastasis with VEGF Inhibitors: Antiangiogenesis RevisitedCancer Cell, 2009
- Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor AngiogenesisCancer Cell, 2009
- Regulation of cancer cell metabolism by hypoxia-inducible factor 1Seminars in Cancer Biology, 2009
- Inhibition of oxygen sensors as a therapeutic strategy for ischaemic and inflammatory diseaseNature Reviews Drug Discovery, 2009
- Oxygen Sensors at the Crossroad of MetabolismCell Metabolism, 2009
- Hypoxia and Aggressive Tumor Phenotype: Implications for Therapy and PrognosisThe Oncologist, 2008
- Molecular aspects of tumour hypoxiaMolecular Oncology, 2008
- Hypoxia — a key regulatory factor in tumour growthNature Reviews Cancer, 2002